X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (23) 23
humans (21) 21
aged (16) 16
bortezomib (16) 16
multiple myeloma - drug therapy (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
hematology (13) 13
treatment outcome (13) 13
female (12) 12
male (12) 12
middle aged (11) 11
multiple myeloma (11) 11
dexamethasone (9) 9
disease-free survival (9) 9
elderly-patients (9) 9
oncology (9) 9
thalidomide - administration & dosage (9) 9
melphalan (8) 8
melphalan - administration & dosage (8) 8
thalidomide - analogs & derivatives (8) 8
multiple myeloma - mortality (7) 7
multiple myeloma - therapy (7) 7
prednisone - administration & dosage (7) 7
thalidomide (7) 7
therapy (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
lenalidomide (6) 6
prednisone (6) 6
stem-cell transplantation (6) 6
thalidomide - adverse effects (6) 6
transplantation (6) 6
abridged index medicus (5) 5
aged, 80 and over (5) 5
antineoplastic agents - therapeutic use (5) 5
kaplan-meier estimate (5) 5
survival (5) 5
thalidomide - therapeutic use (5) 5
boronic acids - administration & dosage (4) 4
cancer (4) 4
chemotherapy (4) 4
dose-response relationship, drug (4) 4
initial treatment (4) 4
multiple myeloma - diagnosis (4) 4
multiple myeloma - pathology (4) 4
plus thalidomide (4) 4
prednisone - adverse effects (4) 4
pyrazines - administration & dosage (4) 4
randomized controlled-trial (4) 4
risk factors (4) 4
boronic acids - therapeutic use (3) 3
clinical trials as topic (3) 3
dexamethasone - administration & dosage (3) 3
italy (3) 3
maintenance (3) 3
melphalan - adverse effects (3) 3
metaanalysis (3) 3
multiple myeloma - genetics (3) 3
multiple myeloma - metabolism (3) 3
multiple-myeloma (3) 3
oral melphalan (3) 3
prednisone plus thalidomide (3) 3
proteasome inhibitors (3) 3
pyrazines - therapeutic use (3) 3
time factors (3) 3
trial (3) 3
adult (2) 2
angiogenesis inhibitors - therapeutic use (2) 2
antibodies, monoclonal - pharmacology (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antineoplastic agents - administration & dosage (2) 2
apoptosis (2) 2
bone-marrow (2) 2
boronic acids - adverse effects (2) 2
care and treatment (2) 2
carfilzomib (2) 2
cell death (2) 2
cell proliferation (2) 2
cyclophosphamide - administration & dosage (2) 2
dexamethasone - therapeutic use (2) 2
disease progression (2) 2
drug administration schedule (2) 2
drug resistance, neoplasm (2) 2
drug therapy, combination (2) 2
drug-resistance (2) 2
elderly patients (2) 2
expression (2) 2
follow-up studies (2) 2
hematology, oncology and palliative medicine (2) 2
induction chemotherapy (2) 2
maintenance chemotherapy (2) 2
maximum tolerated dose (2) 2
medicine & public health (2) 2
melphalan - therapeutic use (2) 2
monoclonal antibodies (2) 2
monoclonal gammopathy (2) 2
neutropenia - chemically induced (2) 2
oligopeptides - administration & dosage (2) 2
original (2) 2
ovarian cancer (2) 2
pharmacology & pharmacy (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1617 - 1629
Summary Background High-dose melphalan plus autologous stem-cell transplantation (ASCT) is the standard approach in transplant-eligible patients with newly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | ONCOLOGY | CONSOLIDATION THERAPY | INITIAL TREATMENT | THALIDOMIDE | BORTEZOMIB | INDUCTION | STEM-CELL TRANSPLANTATION | DEXAMETHASONE COMBINATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Melphalan - therapeutic use | Hematopoietic Stem Cell Transplantation - mortality | Cyclophosphamide - therapeutic use | Thalidomide - analogs & derivatives | Multiple Myeloma - therapy | Time Factors | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Maintenance Chemotherapy | Chemotherapy, Adjuvant | Thalidomide - adverse effects | Prednisone - adverse effects | Multiple Myeloma - diagnosis | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Disease Progression | Disease-Free Survival | Czech Republic | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Thalidomide - therapeutic use | Australia | Prednisone - therapeutic use | Medical colleges | Cyclophosphamide | Care and treatment | Chemotherapy | Dexamethasone | Multiple myeloma | Stem cells | Product development | Prednisone | Transplantation | Cancer | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2014, Volume 32, Issue 7, pp. 634 - 640
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 986 - 993
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label,... 
LOW-DOSE WARFARIN | DEXAMETHASONE | THERAPY | VENOUS THROMBOEMBOLISM | ONCOLOGY | DEEP-VEIN THROMBOSIS | PREDNISONE PLUS THALIDOMIDE | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Warfarin - adverse effects | Male | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Multiple Myeloma - drug therapy | Thromboembolism - prevention & control | Time Factors | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Cardiovascular Diseases - mortality | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Risk Assessment | Multiple Myeloma - complications | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Thromboembolism - etiology | Thromboembolism - mortality | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Hemorrhage - chemically induced | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 03/2011, Volume 152, Issue 5, pp. 579 - 592
Signalling through the interleukin (IL)‐6 pathway induces proliferation and drug resistance of multiple myeloma cells. We therefore sought to determine whether... 
multiple myeloma | siltuximab | Akt | Interleukin‐6 | melphalan | Siltuximab | Melphalan | Multiple myeloma | Interleukin-6 | SURVIVAL | APOPTOSIS | BONE-MARROW | CELL-DEATH | TARGETED INHIBITION | IN-VIVO | ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY | HEMATOLOGY | PROTEASOME INHIBITORS | DEPENDENT MECHANISM | BCL-2 FAMILY | Cell Survival - drug effects | Interleukin-6 - antagonists & inhibitors | Apoptosis - drug effects | Antibodies, Monoclonal - pharmacology | Humans | bcl-2-Associated X Protein - metabolism | Multiple Myeloma - metabolism | Neoplasm Proteins - metabolism | bcl-2 Homologous Antagonist-Killer Protein - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Plasma Cells - drug effects | Melphalan - administration & dosage | Multiple Myeloma - pathology | Signal Transduction - drug effects | Antibodies, Monoclonal - administration & dosage | Melphalan - pharmacology | Tumor Cells, Cultured | Proto-Oncogene Proteins c-akt - metabolism | BH3 Interacting Domain Death Agonist Protein - metabolism | Drug Screening Assays, Antitumor | Interleukins | Cell death | Leukemia | Stem cells | Monoclonal antibodies | Lymphomas | Models | Amyloidosis | Transplantation | Drug resistance | Index Medicus | Cell proliferation | Phosphorylation | Translation | AKT protein | Cytotoxicity | Monoclonal gammopathy | Tumor cell lines | BAK protein | Caspase-3 | phosphoinositides | Caspase-8 | Interleukin 6 | Signal transduction | stromal cells | Caspase-9 | Plasma cells | p70 S6 kinase | Apoptosis
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2014, Volume 89, Issue 4, pp. 355 - 362
Novel agents in combination with melphalan and prednisone (MP) significantly improved progression‐free survival (PFS) and overall survival (OS) in multiple... 
SURVIVAL | THERAPY | METAANALYSIS | EFFICACY | INITIAL TREATMENT | PLUS THALIDOMIDE | RANDOMIZED CONTROLLED-TRIAL | PHASE-3 | HEMATOLOGY | YOUNGER | TRANSPLANTATION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Pyrazines - administration & dosage | Drug Evaluation | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Male | Case-Control Studies | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Aged, 80 and over | Female | Retrospective Studies | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Bortezomib | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Thalidomide - administration & dosage | Randomized Controlled Trials as Topic | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Nervous System Diseases - chemically induced | Aged | Multiple Myeloma - genetics | Evidence, Expert | Medical research | Corticosteroids | Analysis | Multiple myeloma | Medicine, Experimental | Prednisone | Consulting services | Multivariate analysis | Chemotherapy | Ovarian cancer | Index Medicus | Clinical Medicine | Hematologi | Medical and Health Sciences | Hematology | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 45, pp. 79884 - 79896
Background: In cancer patients, malnutrition is associated with treatment toxicity, complications, reduced physical functioning, and decreased survival. The... 
Sarcopenia | Oncology | Cachexia | Malnutrition | Cancer | LUNG-CANCER PATIENTS | cachexia | WEIGHT-LOSS | RISK | oncology | CHEMOTHERAPY | CELL BIOLOGY | malnutrition | MINI NUTRITIONAL ASSESSMENT | ESPEN GUIDELINES | CLINICAL-IMPLICATIONS | cancer | QUALITY-OF-LIFE | DIAGNOSTIC-CRITERIA | sarcopenia
Journal Article